| |
|
|
|
Xtalks, Online
2025-01-23
In this webinar, the expert speakers will review strategies for phase-appropriate assessment of Fc-mediated functional activity and present new developments for complex modalities.
The success of many cancer therapeutics lies in their ability to induce cytotoxicity by NK cells (antibody-dependent cellular cytotoxicity (ADCC)), phagocytosis (antibody-dependent cellular phagocytosis (ADCP)) and complement-dependent cytotoxicity (CDC) against specific targets; therefore, appropriate assessment is crucial before progressing a drug into the clinic.
Importantly, demonstrating the lack of unwanted effector functions is required for safety purposes. During this webinar, the expert speakers will consider the key aspects for developing successful Fc-mediated functional assays and will review the benefits and challenges of a panel of assay formats for different purposes.
They will also present options for choosing the most suitable target cell lines, effector cells and appropriate controls. Moreover, they will showcase studies on how rigorous data trending leads to reliable assays and how more complex formats, such as how real-time spheroid cytotoxicity assays contribute to understanding the mode of action and selecting the most promising lead.
Register for this webinar to obtain an overview of how Fc-mediated functions (or lack of) are essential to the success of biologic drugs and how best to evaluate these functions.
.
Keywords: Cancer, Drug Development, Biologics, CRO, Oncology, Therapeutics, biotherapeutic, Therapeutic Areas, Biologics Manufacturing, Cell & Gene Therapies, Basic Research
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Rosa Gonzalez-Serrano, Senior Manager, Abzena
Erika Kovacs, Senior Director, Abzena
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-01-23
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|